IP Library Granted Patent US 7,368,561
Granted Patent B2
US 7,368,561 · App. 10/535,728 · Granted May 6, 2008

Isolation of antisense oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,561
App. No.
10/535,728
Granted
May 6, 2008
Kind
B2
Abstract

The present invention relates to a method of isolating fully thioated single stranded antisense oligonucleotides from a biological solution, which method comprises the steps of contacting the biological solution with an immobilised metal ion adsorption chromatography (IMAC) resin to adsorb the antisense oligonucleotides to the resin and subsequently contacting the resin with an eluent under conditions that provide desorption of the antisense oligonucleotides from the resin, wherein the fully thioated antisense oligonucleotides are separated from incorrectly thioated antisense oligonucleotides in the solution. The invention also relates to the use of an immobilised metal ion adsorption chromatography (IMAC) resin for isolation of fully thioated single stranded antisense oligonucleotides from a biological solution.

Claims (7)

1. A method of isolating fully thioated single stranded antisense oligonucleotides from a biological solution, which method comprises the steps of contacting the biological solution with an immobilised metal ion adsorption chromatography (IMAC) resin to adsorb antisense oligonucleotides to said resin and subsequently contacting the resin with an eluent under conditions that provide desorption of the antisense oligonucleotides from said resin, wherein the fully thioated antisense oligonucleotides are separated from incorrectly synthesised and/or incorrectly thioated antisense oligonucleotides in said solution; further wherein the metal ion is Zr 2+ or Fe 3+ .

2. The method of claim 1 , wherein the biological solution is a synthesis reaction of antisense oligonucleotides.

3. The method of claim 1 , further wherein fully thioated antisense oligonucleotides are separated from incorrectly synthesised oligonucleotides.

4. The method of claim 1 , wherein fully thioated antisense oligonucleotides are separated from incorrectly thioated antisense oligonucleotides containing 1-5 bonds without thioation.

5. The method of claim 1 , wherein the antisense oligonucleotides are of a size in the range of 5-30 base pairs.

6. The method of claim 1 , wherein the pH of the biological solution is below about 7 during the adsorption of antisense oligonucleotides.

7. The method of claim 1 , which in addition comprises a subsequent step of polishing the isolated antisense oligonucleotides.

Assignments (4)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
CHANGE OF NAME Recorded Feb 21, 2006
From: PHARMACIA FINE CHEMICALS AB; PHARMACIA LKB BIOTECHNOLOGY AB; PHARMACIA BIOTECH AB; APBIOTECH AB; AMERSHAM PHARMACIA BIOTECH AB; AMERSHAM BIOSCIENCES AB
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 017186/0644 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2005
From: ERIKSSON, KJELL; JOHANSSON, BO-LENNART
To: AMERSHAM BIOSCIENCES AB
Reel/Frame 016845/0336 →